BioSpace News Archive

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report fourth quarter and full year 2021 financial results after the U.S. financial markets close on Thursday, March 10, 2022.

Viemed Healthcare, Inc., a home medical equipment supplier and the nation’s largest independent provider of ventilation that provides post-acute respiratory care services, reported its financial results for the three months and year ended December 31, 2021.

Liminal BioSciences Inc., announced that on March 4, 2022, it received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market indicating that the Company is not in compliance with the minimum bid price requirement of US$1.00 per share under the Nasdaq Listing Rules.

Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP; OTCQB:ASPCF) today announced the closing of its previously-announced acquisition of Serenity Pharmaceuticals LLC (“Serenity”), including the global rights to its Noctiva™ brand.

WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced the launch of Tetracycline-Enabled Self-Silencing Adenovirus (TESSA™).

Avinger, Inc. today announced the expansion of first case experience with its new Lightbox 3 imaging console to four additional hospitals in Pennsylvania and New Jersey.

Longeveron Inc. today announced that the Company will release its fourth quarter and year-end 2021 financial results on Friday, March 11, 2022 before the open of U.S. financial markets.

aTyr Pharma, Inc. today announced that it will report fourth quarter and full year 2021 financial results and provide a corporate update after the market close on Monday, March 14, 2022.

Baudax Bio, Inc. announced that the Company received a letter on March 3, 2022 from The Nasdaq Stock Market noting the Company has regained compliance with the minimum bid price requirement under Listing Rule 5550(a)(2), which requires the Company to maintain a minimum closing bid price of $1.00 per share.

Agile Therapeutics, Inc. today announced it will report fourth quarter and full year 2021 financial results after the market close on Wednesday, March 30, 2022.